Literature DB >> 23179814

[Preservative-containing eye drops and adherence in ophthalmological practice].

I Lanzl1, T Kaercher.   

Abstract

Chronic eye diseases, such as glaucoma or dry eye syndrome, require long-term drug application to the eyes. Good adherence is required to achieve the therapeutic goal and patient needs and requirements have to be taken into account. This distinguishes adherence to drug therapy from the former compliance which implies only following medical instructions. Adherence is influenced by socioeconomic, health system-related, disease-related, treatment-related and patient-related factors. It can be measured by tedious procedures, such as electronic monitoring, self-assessment, drop counting and laboratory findings of systemic drug levels. Non-adherence is a growing medical problem worldwide. An increase in adherence means an increased degree of therapeutic safety for the patient and long-term cost savings for the individual as well as society. Non-adherence in chronic diseases, such as glaucoma and dry eye syndrome is increased by eye drops that cause side effects. Often these side effects are caused by agents such as the preservative benzalkonium chloride. To achieve a good adherence preservative-free eye drops are advised.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179814     DOI: 10.1007/s00347-012-2641-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  22 in total

1.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

2.  Health literacy and adherence to glaucoma therapy.

Authors:  Kelly W Muir; Cecile Santiago-Turla; Sandra S Stinnett; Leon W Herndon; R Rand Allingham; Pratap Challa; Paul P Lee
Journal:  Am J Ophthalmol       Date:  2006-08       Impact factor: 5.258

3.  The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity.

Authors:  Betsy Sleath; Susan Blalock; David Covert; Jennifer L Stone; Asheley Cockrell Skinner; Kelly Muir; Alan L Robin
Journal:  Ophthalmology       Date:  2011-12       Impact factor: 12.079

4.  Patient-reported behavior and problems in using glaucoma medications.

Authors:  Betsy Sleath; Alan L Robin; David Covert; John E Byrd; Gail Tudor; Bonnie Svarstad
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

5.  Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma.

Authors:  Gwyneth Rees; Omega Leong; Jonathan G Crowston; Ecosse L Lamoureux
Journal:  Ophthalmology       Date:  2010-02-13       Impact factor: 12.079

6.  An evaluation of how glaucoma patients use topical medications: a pilot study.

Authors:  Tony Tsai; Alan L Robin; Judson P Smith
Journal:  Trans Am Ophthalmol Soc       Date:  2007

7.  Multicenter study of compliance and drop administration in glaucoma.

Authors:  Ramin Kholdebarin; Robert J Campbell; Ya-Ping Jin; Yvonne M Buys
Journal:  Can J Ophthalmol       Date:  2008-08       Impact factor: 1.882

8.  Compliance in patients prescribed eyedrops for glaucoma.

Authors:  S C Patel; G L Spaeth
Journal:  Ophthalmic Surg       Date:  1995 May-Jun

9.  Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union.

Authors:  William C Stewart; Bonnie Kruft; Lindsay A Nelson; Jeanette A Stewart
Journal:  Eur J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 2.597

10.  Compliance barriers in glaucoma: a systematic classification.

Authors:  James C Tsai; Cori A McClure; Sarah E Ramos; David G Schlundt; James W Pichert
Journal:  J Glaucoma       Date:  2003-10       Impact factor: 2.503

View more
  3 in total

Review 1.  [Possibilities and limitations of eye drops for glaucoma therapy].

Authors:  I M Lanzl; M Poimenidou; G L Spaeth
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

2.  Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-An observational cohort study.

Authors:  Stefanie Frech; Daniel Kreft; Rudolf F Guthoff; Gabriele Doblhammer
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

3.  Patient-Reported Nonadherence with Glaucoma Therapy.

Authors:  Christian Wolfram; Erik Stahlberg; Norbert Pfeiffer
Journal:  J Ocul Pharmacol Ther       Date:  2019-03-21       Impact factor: 2.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.